DK Life Science Co., Ltd. (KOSDAQ:303810)
South Korea · Delayed Price · Currency is KRW 2,830.00
+135.00 (5.01%)
Jun 11, 2026, 11:24 AM KST
DK Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 128,377 | 130,344 | 131,816 | 120,161 | 107,234 | 102,668 |
Other Revenue | -0 | -0 | - | -0 | - | - |
| 128,377 | 130,344 | 131,816 | 120,161 | 107,234 | 102,668 | |
Revenue Growth (YoY) | -3.69% | -1.12% | 9.70% | 12.05% | 4.45% | -6.31% |
Cost of Revenue | 94,578 | 97,357 | 103,241 | 94,909 | 85,063 | 80,826 |
Gross Profit | 33,800 | 32,986 | 28,575 | 25,253 | 22,171 | 21,842 |
Selling, General & Admin | 14,880 | 14,865 | 13,995 | 13,795 | 13,833 | 13,700 |
Research & Development | 2,000 | 1,922 | 1,466 | 1,140 | 1,014 | 1,017 |
Amortization of Goodwill & Intangibles | 564.08 | 564.08 | 162.9 | 29.18 | 40.2 | 287.39 |
Other Operating Expenses | 293.11 | 286.67 | 278.48 | 289.6 | 258.83 | 256.82 |
Operating Expenses | 20,419 | 19,941 | 16,659 | 16,723 | 15,941 | 15,045 |
Operating Income | 13,381 | 13,045 | 11,916 | 8,530 | 6,230 | 6,797 |
Interest Expense | -3,633 | -3,776 | -7,988 | -4,994 | -3,620 | -2,441 |
Interest & Investment Income | 1,894 | 1,896 | 1,068 | 98.3 | 152.55 | 69.84 |
Currency Exchange Gain (Loss) | -598.54 | - | - | -124.83 | -44.41 | -212.04 |
Other Non Operating Income (Expenses) | -134.69 | -395.23 | -253.38 | 2,241 | 2,241 | -981.23 |
EBT Excluding Unusual Items | 10,909 | 10,770 | 4,743 | 5,750 | 4,959 | 3,232 |
Gain (Loss) on Sale of Investments | -48.99 | - | - | -1,670 | 321.86 | 3,236 |
Gain (Loss) on Sale of Assets | -36.5 | 58.39 | 9.63 | 749.93 | - | -34.43 |
Pretax Income | 10,823 | 10,829 | 4,753 | 4,830 | 5,281 | 6,433 |
Income Tax Expense | 2,109 | 2,171 | 2,508 | 663.28 | 1,041 | 575.2 |
Net Income | 8,714 | 8,658 | 2,245 | 4,167 | 4,239 | 5,858 |
Net Income to Common | 8,714 | 8,658 | 2,245 | 4,167 | 4,239 | 5,858 |
Net Income Growth | 129.20% | 285.71% | -46.13% | -1.71% | -27.63% | 31.49% |
Shares Outstanding (Basic) | 32 | 32 | 28 | 11 | 1 | 1 |
Shares Outstanding (Diluted) | 32 | 32 | 28 | 11 | 1 | 1 |
Shares Change (YoY) | -2.12% | 12.34% | 150.51% | 900.58% | 0.01% | -2.05% |
EPS (Basic) | 272.08 | 274.68 | 80.00 | 372.00 | 3787.00 | 5233.00 |
EPS (Diluted) | 272.08 | 274.68 | 80.00 | 372.00 | 3787.00 | 5233.00 |
EPS Growth | 134.15% | 243.35% | -78.50% | -90.18% | -27.63% | 34.25% |
Free Cash Flow | -1,243 | -5,257 | 6,455 | -9,398 | -20,287 | -24,739 |
Free Cash Flow Per Share | -38.82 | -166.78 | 230.04 | -839.06 | -18122.49 | -22100.17 |
Gross Margin | 26.33% | 25.31% | 21.68% | 21.02% | 20.68% | 21.27% |
Operating Margin | 10.42% | 10.01% | 9.04% | 7.10% | 5.81% | 6.62% |
Profit Margin | 6.79% | 6.64% | 1.70% | 3.47% | 3.95% | 5.71% |
Free Cash Flow Margin | -0.97% | -4.03% | 4.90% | -7.82% | -18.92% | -24.10% |
EBITDA | 19,873 | 19,456 | 17,698 | 11,813 | 8,691 | 9,181 |
EBITDA Margin | 15.48% | 14.93% | 13.43% | 9.83% | 8.11% | 8.94% |
D&A For EBITDA | 6,492 | 6,411 | 5,782 | 3,283 | 2,461 | 2,385 |
EBIT | 13,381 | 13,045 | 11,916 | 8,530 | 6,230 | 6,797 |
EBIT Margin | 10.42% | 10.01% | 9.04% | 7.10% | 5.81% | 6.62% |
Effective Tax Rate | 19.48% | 20.04% | 52.77% | 13.73% | 19.72% | 8.94% |
Advertising Expenses | - | 2,308 | 1,866 | 2,344 | 1,748 | 1,552 |